M&A / Deals Kailera makes history with record-breaking $625m IPO Pharmaceutical TechnologyKailera's IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaceutical Technology Kailera’s IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials. M&A / DealsRead full story Post navigation Previous: Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery toolNext: Trump signs order to hasten psychedelic medicine access Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
